Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Chuikyo Calls for Combining Multiple Steps to Curb Spend for Potential Super Big Sellers Like Aducanumab, No Objection to Listing
Both payer and healthcare provider members of Japan’s key drug pricing panel on November 5 called for controlling spending of potentially super-big-seller medicines that might rake in annual revenue of hundreds of billions of yen by combining and even tightening…
To read the full story
Related Article
- Chuikyo Split over 2% Adjustment Rate, Off-Year Re-Pricing; JPWA Says Wholesalers Are in Dire Straits
November 8, 2021
- Industry Pushes PMP Coverage for Additional Indications, Payers See This Need Too but Only for Certain Products: Chuikyo
November 8, 2021
- JGA Sees New Generics as Financial Resources Necessary to Increase Production Capacity: Chuikyo Hearing
November 8, 2021
- Chuikyo Discusses Spillover Rules in Market Expansion Re-Pricing, PMP Criteria towards FY2022 Reform
October 21, 2021
- Chuikyo Calls for Balanced Price-Setting for “Specific-Use” Drugs, Sakigake Products
August 5, 2021
- Pharma Groups Want Price Maintenance for Patented Meds, Payer Sees It “Natural” to Rectify Gap: Chuikyo
May 13, 2021
- Chuikyo Reps Warn Each Other over 2% Adjustment Rate in Drug Price Revisions
April 22, 2021
- MHLW Presents Discussion Timeline for FY2022 Reform
April 15, 2021
REGULATORY
- Japan to Ease Olanzapine Diabetes Contraindication for Antiemetic Use
July 31, 2026
- Pipe Damage Causes Water Leak at Sawai Plant after Quake: MHLW
July 30, 2026
- MHLW Urges Stable Supply of Drugs after Kumamoto Earthquake
July 30, 2026
- Kumamoto Quake Hits 46 Medical Facilities; No Pharma Damage Yet: MHLW
July 29, 2026
- Japan Shifts Mo-99 Supply Strategy toward Stronger Global Procurement: Panel
July 29, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…